A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID

A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID
Peluso et al., medRxiv, doi:10.64898/2026.03.07.26347857 (results released 10/28/25)
https://c19early.org/peluso3.html